Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Merkel Cell 2Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

pembrolizumab 9avelumab 9Nivolumab 8atezolizumab 4Specimen Handling 4durvalumab 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3Biopsy 3ALT-803 3talimogene laherparepvec 2fludarabine phosphate 2fludarabine 2domatinostat 2Radiosurgery 2Ipilimumab 2Cisplatin 2Carboplatin 2relatlimab 1oblimersen 1lutetium Lu 177 dotatate 1lenvatinib 1lanreotide 1daromun 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Merkel Cell × domatinostat × Clear all
NCT04393753 2024-05-08

MERKLIN2

4SC AG

Phase 2 Completed
19 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT04874831 2021-11-18

Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)

4SC AG

Phase 2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡